Stockscreener 앱 받기
1.71
3.39%
-0.06
시간 외 거래:
1.71
전일 마감가:
$1.77
열려 있는:
$1.8
하루 거래량:
521.63K
Relative Volume:
0.82
시가총액:
$77.76M
수익:
$19.94M
순이익/손실:
$-37.37M
주가수익비율:
-1.3465
EPS:
-1.27
순현금흐름:
$-33.38M
1주 성능:
-22.27%
1개월 성능:
-16.59%
6개월 성능:
-63.77%
1년 성능:
-25.65%
1일 변동 폭
$1.70
$1.8121
1주일 범위
$1.70
$2.235
52주 변동 폭
$1.66
$8.1939
웨어울프 테라 Stock (HOWL) Company Profile
명칭
Werewolf Therapeutics Inc
전화
617-952-0555
주소
200 TALCOTT AVENUE, WATERTOWN
HOWL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| HOWL | 1.71 | 77.76M | 19.94M | -37.37M | -33.38M | -1.27 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
웨어울프 테라 Stock (HOWL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-03 | 개시 | JMP Securities | Mkt Outperform |
| 2023-08-24 | 개시 | Wedbush | Outperform |
| 2023-06-06 | 재개 | Jefferies | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-25 | 개시 | Evercore ISI | Outperform |
| 2021-05-25 | 개시 | H.C. Wainwright | Buy |
| 2021-05-25 | 개시 | Jefferies | Buy |
| 2021-05-25 | 개시 | SVB Leerink | Outperform |
모두보기
웨어울프 테라 주식(HOWL)의 최신 뉴스
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Equities Analysts Set Expectations for HOWL FY2024 Earnings - MarketBeat
Werewolf Therapeutics' SWOT analysis: oncology biotech's stock potential amid clinical progress - Investing.com Australia
What is HC Wainwright's Forecast for HOWL Q1 Earnings? - MarketBeat
Werewolf Therapeutics reports promising trial data for cancer drug By Investing.com - Investing.com South Africa
Werewolf Therapeutics Inc (HOWL) Quarterly 10-Q Report - Quartz
Werewolf Therapeutics reports promising trial data for cancer drug - Investing.com
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Presents Preclinical and Clinical - GlobeNewswire
Werewolf's WTX-330 Shows Promise in Phase 1 Trial: Melanoma Patient Responds to Novel IL-12 Therapy | HOWL Stock News - StockTitan
Werewolf Therapeutics Reports Breakthrough Cancer Trial Results Despite $16.7M Loss | HOWL Stock News - StockTitan
Werewolf Therapeutics announces IL-10 Indukine development candidate for inflammatory bowel disease - BioWorld Online
Werewolf Therapeutics expands pipeline with new IBD candidate By Investing.com - Investing.com South Africa
Werewolf Therapeutics expands pipeline with new IBD candidate - Investing.com
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases - The Manila Times
Werewolf Therapeutics Announces Promising New Development - GlobeNewswire
WisdomTree Inc (NYSE: WT): Blank Check On Growth? - Stocks Register
Werewolf To Provide Clinical Update On WTX-330 - RTTNews
Werewolf Therapeutics Inc (NASDAQ: HOWL) Could Pass $12 In One Year Stock Forecast - Stocks Register
Social Security Just Released the 2025 COLA. Here's What It Means for Those Receiving Spousal Benefits. - Yahoo! Voices
Could Buying Apple Stock Today Set You Up for Life? - Yahoo! Voices
Is Summit Therapeutics Inc. (SMMT) the Best QQQ Stock to Buy According to Analysts? - Yahoo Finance
Lyft is working on a ‘service animal opt-in feature’ for passengers - Yahoo! Voices
Hammond packaging facility to get $35M upgrade - Yahoo! Voices
2 Game-Changing Artificial Intelligence (AI) Stocks to Buy Right Now (Hint: Not Nvidia) - Yahoo! Voices
Poland’s stunning success should be discomforting for Britain - Yahoo! Voices
Every UPS Investor Should Keep an Eye on This Number - Yahoo! Voices
Billionaire Philippe Laffont Just Increased His Position by 139% in This Data Center Opportunity (Hint: It's Not Nvidia) - Yahoo! Voices
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance
ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Cut the state to get growing - Yahoo! Voices
‘It’s huge’: Striking Boeing workers near deal - Yahoo! Voices
National Association of Black Accountants’ St. Louis Chapter honors 50 years of community impact - Yahoo! Voices
Voya Financial Reports $341 Billion AUM Milestone - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
mRNA licensing agreements surge 800% amid GSK lawsuits - Yahoo Finance
State Street Corp's Strategic Reduction in Viridian Therapeutics Inc - Yahoo Finance
State Street Corp's Strategic Reduction in Viking Therapeutics Holdings - Yahoo Finance
Nvidia to be the first company to hit $4T market cap: Lumida CEO - Yahoo Finance
LGT incorporates its Barcelona digital hub - Yahoo News
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar? - Yahoo Finance
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Yahoo Finance
NantHealth (NASDAQ:NH) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Downgrades Nomad Foods (NYSE:NOMD) to Hold - Defense World
Microsoft said it lost weeks of security logs for its customers' cloud products - Yahoo! Voices
TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics - Yahoo Finance
State Street Corp's Strategic Acquisition in Beam Therapeutics Inc - Yahoo Finance
Walgreens has more than 100 stores in Indiana. Company plans to shut down 1,200 nationwide - Yahoo News
Dogwood Therapeutics, Inc. Expected to Earn Q3 2024 Earnings of ($1.40) Per Share (NASDAQ:DWTX) - Defense World
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug - Yahoo Finance
웨어울프 테라 (HOWL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):